We and others recently isolated a human p53 homologue (p40͞p51͞p63͞p73L) and localized the gene to the distal long arm of chromosome 3. Here we sought to examine the role of p40͞p73L, two variants lacking the N-terminal transactivation domain, in cancer. 
A
lterations of the p53 tumor-suppressor gene and its encoded protein are the most frequently encountered genetic events in human malignancy (1) . It is now established that the p53 protein is central to the cellular response to a wide variety of stressful stimuli. These stimuli, which include DNA damage, hypoxia, heat shock, metabolic changes, and certain cytokines, activate the p53 protein, which in turn drives a series of events that culminate in cell cycle arrest or apoptosis (2, 3) .
The importance of p53 in both normal homeostasis of a cell and tumorigenesis drove the search for homologues of p53. The p53-related gene p73 (located on chromosomal arm 1p) was reported, showing strong sequence homology with various key regions of p53 (4) . However, despite its location within a tumor suppressor locus and its ability to mimic p53 in certain transcriptional and growth control assays, the role of p73 in human cancers is still unclear. Unlike p53, p73 was induced only by cisplatin and not by other agents that induce damage (5) . Moreover, the remaining allele in neuroblastomas that have undergone loss of heterozygosity was not inactivated (6) .
Using degenerate PCR primers based on conserved regions in the DNA-binding domains of p53 and p73, we cloned an additional member of this family, p40 (7) . Concurrently, other groups cloned different isoforms of the same gene and referred to their products as p51, p63, and p73L (8) (9) (10) . The main difference between the various transcripts is the presence or absence of the N-terminal transcriptional activation (TA) domain; p40, ⌬Np63, and p73L lack this domain.
One alternative transcript containing a TA domain (p51) was shown to suppress colony formation and to transcriptionally activate p21 in a fashion similar to the p53 tumor suppressor gene (8) . However, a transcript lacking the N-terminal transactivation domain was found to act in a dominant-negative fashion and was able to suppress p53 transactivation (9) .
We found no evidence of a tumor suppressor function for the p40͞p51͞p63͞p73L gene. Instead, we observed overexpression of this gene in head and neck cancer cell lines and primary lung cancers associated with a low increase of its copy number. Because this gene is amplified in squamous cell carcinoma, we now refer to it as AIS. Moreover, because multiple products of the AIS gene share the central core domain (p40 AIS ), we used this protein in functional studies. In transformation assays, Rat 1a cells with p40 AIS expression developed larger colonies in soft agar and bigger tumors in nude mice compared with cells with an empty vector. Our data thus support the concept that AIS transcripts lacking the TA domain may play an oncogenic rather than a suppressive role in certain cancers.
Materials and Methods
Tumor Source and Cell Lines. Primary tumors were collected from patients diagnosed with head and neck carcinoma or lung carcinoma between the years 1993 and 1999 at The Johns Hopkins University. Fresh tumors were obtained from surgical resection and stored at Ϫ80°C for DNA and RNA analysis. Paraffin blocks were made available from the department of pathology for immunohistochemical analysis. All cell lines were isolated in the Department of Otolaryngology at The Johns Hopkins University (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) with the exception of SaOs2, FaDu, and HEK293, which were obtained from the American Type Culture Collection.
Mutation Analysis. The PCR amplification of tumor cDNA samples consisted of 35 cycles at 95°C for 1 min, 55°C for 1 min, 72°C for 1 min. The primers used for p40 amplification were S1 (sense), 5Ј-GCAGCATTGATCAATCTTACAG and AS2 (antisense), 5Ј-TGAATTCACGGCTCAGCTCAT; S3 (sense), 5Ј-CGCCATGCCTGTCTACAAAAA and AS4 (antisense), 5Ј-GCCTCCTAAAATGACACGTTG. All PCR products were purified and sequenced directly with the AmpliCycle sequencing kit (Perkin-Elmer). The sequencing primers were 5Ј-GCCACAGTACACGA ACCTGG, 5Ј-A A A AGCTGA-GCACGTCACGG, 5Ј-CT TCACCACCTCCGTGACGT, 5Ј-AGGT TGGCACTGA AT TCACGA, 5Ј-A A A AT TG-GACGGCGGTTCAT, 5Ј-GTGATGGTACGAAGCGCCC, and 5Ј-ACGGGCGCTTCGTACCAT. Mutation analysis for the p53 gene was performed as described previously (11) .
AIS Adenovirus. A full-length p40 AIS cDNA was cloned from a human prostate cDNA library as previously described (7). The Abbreviations: TA domain, transcriptional activation domain; FISH, fluorescent in situ hybridization; HNSCC, head and neck squamous cell carcinoma; RT-PCR, reverse transcription-PCR.
construct was then subcloned into the shuttle vector, pAdTrack-CMV. The resultant plasmid was linearized by digesting with the restriction endonuclease PmeI, and subsequently cotransformed into Escherichia coli BJ5183 cells with an adenoviral backbone plasmid, pAdEasy-1. Recombinants were selected for kanamycin resistance, and recombination was confirmed by restriction digest analysis. The linearized recombinant plasmid was then transfected into the adenovirus packaging cell line, HEK-293, which was described in detail previously (12) .
Northern Analysis. For primary tissues, the collected samples were grossly dissected and quickly frozen or lysed immediately in the guanidine buffer, and the RNA was isolated by using a CsCl gradient method. For cancer cell lines, total RNA was isolated by using the Trizol reagent (GIBCO͞BRL). Northern blot hybridization using the cDNA probes was performed as described (13) .
Fluorescent in Situ Hybridization (FISH) Analysis. FISH was performed as previously described (14) . Specifically, 4-m-thick sections were cut out and mounted on glass slides, fixed in a methanol and glacial acetic acid (3:1) solution for 5 min, and then dehydrated in ethanol series and allowed to air dry. Cell lines were fixed in the same fixative described above and dropped onto glass slides. Samples were denatured in 70% formamide and 2ϫ SSC at 75°C for 5 min, followed by dehydration in cold ethanol. The bacterial artificial chromosome (BAC) probe containing AIS was isolated as described (7) and was labeled by nick translation with digoxigenin-11-dUTP (Boehringer Mannheim), and the biotin-labeled centromere probe for chromosome 3 was purchased from Vysis (Downers Grove, IL). The hybridization mixture consisted of 10% dextran sulfate, 50% formamide, 2ϫ SSC, 0.1 g of the labeled probe, 10 g of Cot-1 DNA (GIBCO͞BRL), and 10 g of salmon sperm DNA. Before hybridization, the mixture was denatured at 75°C for 5 min and then incubated at 37°C for 15 min. The probes were hybridized overnight to denatured tissue sections at 37°C. After hybridization, slides were washed for 5 min with 0.5ϫ SSC at 72°C and then incubated with rhodamine-anti-digoxigenin and FITCavidin (Oncor). The samples were counterstained with 2-phenylindole⅐dihydrochloride and examined under a Zeiss Axiophot epifluorescence microscope. Tumor areas were determined by evaluating the hematoxylin-and eosin-stained adjacent sections. Up to 200 nuclei per slide signals were counted under a double-band pass filter. The number of AIS and chromosome 3 signals was counted for each nucleus. When the AIS-tochromosome 3 ratio was less than 1, we defined it as not amplified. When it was more than 1, we defined it as a relative amplification of AIS. FISH on normal specimens or nonmalignant areas was analyzed in the same manner as a control. For documentation, images were captured by a charge-coupled device camera (Photometrics, Tucson, AZ) and processed by using the Oncor Image analyzing system.
Immunohistochemistry. Sections 6 m thick were made from paraffin tissue blocks and the slides were dried at 60°C for 30 min, treated with xylenes, and then dehydrated in alcohol. Endogenous peroxidase was blocked with 0.3% H 2 O 2 . After blocking with normal goat serum, the slides were incubated with the polyclonal rabbit antiserum against AIS at 1:2000 dilution for 1 h at room temperature. A polyclonal antibody was made against a specific peptide (residues 5-17, ENNAQTQFSEPQY); this antibody recognizes the AIS isoforms without the TA domain. A Vectastain ABC Kit and DAB Substrate Kit (Vector Laboratories) were used to visualize the antibody binding.
Immunohistochemical analysis for AIS protein was interpreted to determine AIS-positive and -negative staining. Only nuclear staining was interpreted as positive. For control studies, head and neck squamous cell carcinoma (HNSCC) cell line 022 and lung cancer cell line H1299 were used as positive and negative controls, respectively. The AIS status of these two cell lines was confirmed by Northern analysis. Optimized conditions were then used for the immunostaining of primary lung cancer specimens. For confirmation of the specificity of the anti-AIS antibody, we performed Western analysis using SaOs2 [negative for all AIS transcripts by reverse transcription (RT)-PCR], p40 AIS adenovirus-infected SaOs2, and an HNSCC cell line (022). We identified a specific band in each positive control cell lysate with the AIS antibody, whereas no bands were detected with preimmune serum. Unless stated otherwise, this polyclonal antibody (Oncogene Research Products, Cambridge, MA) was used in all protein studies.
Western Analysis. Cells from a T-75 flask were trypsinized and washed with phosphate-buffered saline (PBS) and suspended in 200 l of RIPA buffer (50 mM Tris⅐HCl, pH 7.5͞150 mM NaC1͞1% Nonidet P-40͞0.5% sodium deoxycholate͞0.1% SDS) containing 1 mM PMSF. The lysate was incubated on ice for 20 min, followed by sonication for 5 sec and further incubated for another 20 min on ice. The lysate was then centrifuged at 10,000 rpm in a microcentrifuge for 10 min and supernatant was saved at Ϫ80°C. Proteins in 100-g samples of cell lysates were separated on an SDS 10% polyacrylamide gel and transferred to a poly(vinylidene difluoride) (PVDF) membrane (Micron Separations, Westboro, MA) or a nitrocellulose membrane (Sartorius). After the nonspecific sites had been blocked by incubation in PBS ϩ 5% nonfat dry milk, the blot was incubated with the polyclonal anti-AIS antibody at 1:2000 dilution for 1 h at room temperature. To identify the various AIS isoforms in HNSCC cell lines, we used commercial antibodies to p63 (N-18, 8C-8369), p63␥ (R-20, SC-7255), and p63␣ (C-18, SC-8370) from Santa Cruz Biotechnology. After washing, an ECL kit (Amersham) was used to visualize the antibody binding to each protein. The PVDF membrane was then washed to get rid of attached antibody and reacted with antibody against actin (Chemicon) as an internal control.
Transfection Assay. A full-length p40 AIS cDNA was cloned into pCEP4 (Invitrogen). pCEP4-p40 AIS and pCEP4 were transfected into Rat 1a fibroblast cells by using Lipofectamine (GIBCO͞BRL) according to the protocol provided by the manufacturer. Cells were selected with hygromycin B at 200 g͞ml, and p40 AIS expression in Rat 1a-p40 AIS cells was confirmed by immunohistochemistry.
Tumorigenicity Assay. For soft agar analysis, 10 5 cells of either Rat 1a-p40 AIS or Rat 1a-no (vector only control) in 2-foldconcentrated DMEM͞20% FBS were mixed with an equal volume of 0.8% agarose and poured onto a bed of 0.7% agarose. After 18 days, colonies were counted and measured under the microscope. All experiments were performed in triplicate, and differences were analyzed by the t test.
Tumor growth in nude mice was assayed by inoculating 5 ϫ 10 6 cells of either Rat 1a-p40 AIS or Rat 1a-no into the right or left flank, respectively, of five nude mice. At 21 and 24 days after inoculation, tumor size was measured in three dimensions. Differences in tumor volumes were analyzed by the t test.
Results
We and others recently described several splice variants of a p53 homologue (AIS) on chromosome 3q as shown in Fig. 1 (7-10) . We first examined AIS for mutations by using cDNA prepared by RT-PCR from 14 primary lung cancers and 6 HNSCC cell lines (Table 1) . Two missense variants were observed. These changes involved codon 298 (Lys to Arg) in a primary lung cancer and codon 14 (Glu to Gln) in an HNSCC. Although paired normal DNA was not available to confirm the somatic origin of these alterations, the conserved nature of these missense variants suggested that inactivation of the gene locus in these human cancers is not common.
Because of its structural similarity to p53, we next examined whether AIS demonstrated tumor-suppressive effects when constitutively expressed in cultured cells. SaOs2 cells, which have no expression of p53 (p53 Ϫ͞Ϫ), and AIS (null by RT-PCR) were infected with either a replication-incompetent adenovirus containing p40 AIS under the control of the cytomegalovirus promoter or a empty adenovirus [multiplicity of infection (MOI) ϭ 3]. Cell numbers were determined on days 1, 3, 5, and 7 after infection. Although the p40 AIS adenovirus-infected cells demonstrated abundant p40 AIS protein, there was no difference in cell number or viability compared with the control (data not shown). In contrast, SaOs2 cells infected with a p53 adenovirus showed rapid cell death within 48 h of infection. Overall, these results provided no evidence for a tumor suppressor gene function for variants lacking the N-terminal transactivation domain.
We then examined AIS expression in primary lung cancers and HNSCC cell lines by Northern analysis. We found that 10 of 14 primary lung cancers (71%) and all 6 HNSCC cell lines (100%) had an overexpressed message with the AIS probe, whereas normal paired lung tissue and a normal embryonic lung cell line revealed virtual absence of gene expression ( Fig. 1; Fig. 2) . To explore the possibility that this overexpression was a result of gene amplification, we performed FISH analysis in these tumors (Fig. 3) . FISH analysis demonstrated 2-to 5-fold amplification of the AIS gene locus in 12 of 23 primary lung cancers (52%), all 9 primary HNSCC (100%), and all 6 HNSCC cell lines (100%) ( Table 1) . In some cases, a concordant increase in chromosomal arm 3q with a centromeric probe was also observed, confirming the presence of polysomy. The amplification data from FISH analysis correlated with the expression data from Northern analysis in all of the 6 HNSCC cell lines and the squamous cell lung cancers (see below).
Because of the multiple transcripts derived from the same locus, we tested for AIS protein (p40 AIS and p68 AIS ) expression in primary lung cancers, HNSCC cell lines, and primary HNSCC by using immunohistochemistry. To address the specificity of our antibody, Western blot analysis was performed with lysates from SaOs2 (negative for all AIS transcripts by RT-PCR), SaOs2 transfected with a p40 AIS adenovirus, and the AIS-amplified HNSCC cell line (022). We were able to identify a specific band at approximately 40 kDa in the SaOs2 cell line infected with the p40 AIS adenovirus and a band at approximately 70 kDa corresponding to p68 AIS (or ⌬Np63␣) in the 022 cell line (Fig. 4A) . A similar 68-kDa protein was detected in other HNSCC cell lines (Fig. 4B) . We then probed the Western blots with commercial antibodies specific to the TA domain and the ␣ and ␥ C terminals. Only the p68 AIS product with the ␣ C terminal was consistently overexpressed in the cell lines (data not shown). Some of the cell lines (011, 012, 029) also had low levels of TA-AIS isoforms (data not shown).
By immunohistochemistry, 10 of 23 primary lung cancers (43%), 6 HNSCC cell lines (100%), and all 9 primary HNSCC (100%) had strong positive staining with our polyclonal anti- Fig. 1 . The recent cloning of these variants by several groups (7-10, 29) has led to a potentially confusing nomenclature. Because this gene locus is amplified in squamous cell carcinoma, we renamed the gene AIS, with further designations of splice variants as listed above based on their predicted molecular weight. Note that p68 AIS (p73L) described here is ⌬Np63␣͞CUSP and not p73 encoded on chromosome 1. body, consistent with p68 AIS protein overexpression observed in cell lines (Fig. 5) (Table 1) . As shown previously, nuclear staining was present at the basal layer of the bronchial epithelium (9) . Nuclear expression was characteristic of those cancers with increased protein. Interestingly, all of the positive samples were squamous cell carcinomas and all had chromosome 3 polysomy or more specific AIS amplification (Table 2 ). In contrast, no adenocarcinomas of the lung had protein overexpression (P Ͻ 0.0001, Fisher's exact test), suggesting that AIS amplifi- (Table 2 ). (ϫ200.) cation correlates with abundant protein only in squamous cell carcinoma.
To examine a possible relationship between AIS gene amplification and p53 status, we proceeded with sequence analysis of the p53 gene (exons 5 to 8) in the primary lung cancers. Remarkably, 8 of 10 primary lung cancers with p68 AIS protein overexpression (80%) also harbored p53 mutations. (Table 2 ). This association suggested a possible relationship between overexpression of AIS and p53 inactivation in human cancers.
The potential oncogenic role of p40 AIS was tested in Rat 1a cell clones that overexpressed the protein (Rat 1a-p40 AIS ) or vector only controls (Rat 1a-no). The transformed phenotype of these cell lines was initially assayed by culture in soft agar. Rat 1a-p40 AIS cells displayed a significantly increased frequency of colony formation and larger colonies compared with Rat 1a-no cells (Table 3) . Pooled clones overexpressing p40 AIS were inoculated into nude mice to examine the tumorigenicity of the gene in vivo. Tumor size was measured at 21, 24, and 31 days after inoculation, and we found that Rat 1a-p40 AIS cells produced significantly larger tumors compared with Rat 1a-no cells (Fig.  6 ). These observations suggest that AIS overexpression results in an increased tumorigenic phenotype and further support its role as an oncogene.
Discussion
Despite the initial enthusiasm surrounding the cloning of a family of p53 homologues, there has been little evidence to date as to the role of these genes in the development of human cancers. A role for p73 (1p36) in c-abl-mediated apoptosis was recently proposed (15) . Abnormal expression of p73 has been seen in certain cancers but has been disputed by others (16, 17) . Although AIS 3q27 splice variants with a TA domain have been shown to be growth suppressive (8) , the most commonly occurring isoform in normal tissue and tumor cells is p68 AIS (18) . These observations and our results do not support a tumorsuppressor role for these gene in head and neck and lung cancers. 
*Five primary lung cancers only had total RNA available for analysis. † P Ͻ 0.0001 (Fisher's exact test for squamous cell carcinoma vs. adenocarcinoma). Our data for AIS gene amplification are consistent with recent reports indicating the presence of amplification of chromosomal arm 3q in squamous cell lung carcinoma. Comparative genomic hybridization (CGH) studies indicate that squamous cell lung carcinomas commonly display overrepresentation of the distal arm of chromosome 3q (20) . In one study, two candidate genes, BCHE and SLC2A2, were identified as possible oncogenes because of overexpression in 40% of squamous cell lung carcinomas (21) . We have demonstrated consistent overexpression of AIS at the RNA and protein level in those squamous cell carcinomas with an increase in gene copy number. This combined evidence strongly suggests a role for AIS in the progression of these cancers.
Further support for the oncogenic role of AIS protein products comes from our functional assays. Because the locus contains several variants lacking the TA domain with alternate 3Ј ends ( Fig.  1) we used the core domain p40 AIS in our functional studies. Overexpression of p40 AIS in Rat 1a cells led to a significant increase in the number and size of colonies in soft agar consistent with previous results in bona fide oncogenes (22, 23) . Although p68 AIS is the predominantly overexpressed isoform in human tumors, the ability of these p40 AIS -overexpressing cells to form larger tumors in nude mice supports the idea that AIS overexpression provides a growth advantage to tumor cells in vivo. Because of the high frequency (60%) of amplification and overexpression in lung and head and neck cancer, AIS activation may represent one of the most common oncogenic events in human cancer. Other oncogenes such as K-ras or cyclin D1 are activated or amplified much less frequently in these cancers (24, 25) . One recent study also suggests that p68 AIS overexpression is also common in squamous cell carcinoma of the cervix (26) .
Although p73 (located on chromosome 1p) and some splice variants of AIS contain a putative transactivating domain capable of inducing apoptosis and tumor suppression, there has been little evidence of inactivating point mutations or other evidence of gene inactivation in human tumors (4, 6, 19 ). It appears that AIS protein products lacking the acidic N-terminal domain can act in a dominant-negative fashion to diminish transactivation by p53. This led to the initial thought that one of these variants may behave as an oncogene in this context by interfering with p53 function in a competitive manner (9) . However, our work suggests that at least in squamous cell cancer, p53 mutations and AIS overexpression commonly occur together. Work in progress suggests a direct protein-protein interaction between p40 AIS and wild-type p53 and probably explains the diminution of p53 transactivation in these assays (9) . However, it is quite possible that p40 AIS may have a gain-of-function phenotype over and above a dominant-negative interaction with p53. Further work will help to elucidate the oncogenic function of AIS in the progression of human cancer.
Two recent reports describe knockout of the AIS locus (and all of the transcribed variants) in mice and intriguing developmental defects (27, 28) . The skin of these deficient mice does not progress past an early stage in ectodermal development. Moreover, the embryonic epidermis of these knockout mice undergoes an unusual process of nonregenerative differentiation leading to complete absence of all squamous epithelia. The AIS locus may thus be critical for progenitor cell populations to maintain continued epithelial development. Overexpression of AIS may lead to an increased capacity for epithelial stem cell renewal and the capacity for neoplastic growth. Our data further support the idea that AIS amplification and p68 AIS overexpression may play a role in the development of squamous cell carcinoma. Moreover, p53 and AIS alterations commonly occur together, suggesting that AIS amplification may result in a p53-independent pathway of squamous cell carcinoma transformation.
